Tarsus Pharmaceuticals stock
TARSNASDAQTarsus Pharmaceuticals, Inc., HealthcareISIN US87650L1035
43Score 43 out of 100, Weak
Price and trend
85 / 100
Price history
+2.8% in one yearThe chart shows daily closes over 6 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 13% above it.
Since September 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 69).
The price is 15% below its 52-week high. Largest decline in 6 years: 78% (December 2020 to May 2022).
Chart figures for advanced users
- SMA 50$74.90
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$67.90
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)69
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$56.11
- The lowest closing price of the last twelve months.
- Resistance$90.78
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Tarsus Pharmaceuticals, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $3.79B, is number 88 of 296 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $451.36M (up 146.7% year on year) and a loss of $66.42M.
- For fiscal 2026, analysts expect on average revenue of $741.28M (up 64.2%) and adjusted earnings per share of −$15.55.
Show more
- MEQIRI Score 43 out of 100 (Weak): rank 513 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $309.61M, financial debt $88.67M.
Weaknesses
- DilutionShare count up 106% since 2020.Capital allocation 18
- Loss-makingLoss of $702.23M over the last 12 months.Fundamentals 17
Its standout strengths are technical analysis and momentum, while capital allocation and fundamentals hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 41 to 43.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredClosing price of 11 Nov 2026, used by the daily score.
A fair value is not meaningful here, so the signal follows the valuation grade.
Valuation metrics
The model puts the fair value at less than a quarter of the share price. That says more about the assumptions than about the company, so a fair value is not meaningful here and the valuation relies on the P/E and the other metrics.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 86.3% on the twelve months before. Revenue turned from negative at the start of the period to positive ($451.36M in the latest year).
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 93%, operating −16%, net −15%. Last 12 months: net −100%.
Debt & balance sheet
latest quarterDebt is moderate, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 22 Feb 2027in 102 days
- Last reported
- 3 Nov 2026EPS reported −$14.40 (expected −$1.46)below expectations
Analyst estimates
Analysts have cut their 2026 earnings estimate by 660.5% since 15 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- −$15.55−660.5%
- Revenue
- $741.28M+3.2%
- Earnings per share
- $0.45−69.1%
- Revenue
- $941.31M+2.6%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +5.7%XDEMVY net product sales guidance raised to $685 million to $705 million from $670 million to $700 million.
“We have updated our outlook for the remainder of 2026 and increased XDEMVY full year net product sales guidance to $685 million to $705 million from our prior guidance of $670 million to $700 million.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 6 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 6 insiders sold, $7.65M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Link William J PhdSale
15 Sept 2026, Board
- Shares
- 12,500
- Price
- $78.38
- Value
- $979,744
- Azamian Bobak R.Sale
4 Sept 2026, President/CEO and Board Chair
- Shares
- 10,000
- Price
- $90.56
- Value
- $905,600
- Lin Elizabeth YeuSale
4 Sept 2026, Chief Medical Officer
- Shares
- 13,953
- Price
- $87.50
- Value
- $1.22M
Show 8 more
- Neervannan SeshadriSale
4 Sept 2026, Chief Operating Officer
- Shares
- 4,564
- Price
- $85.00
- Value
- $387,940
- Azamian Bobak R.Sale
2 Sept 2026, President/CEO and Board Chair
- Shares
- 10,000
- Price
- $80.06
- Value
- $800,600
- Lin Elizabeth YeuSale
2 Sept 2026, Chief Medical Officer
- Shares
- 6,977
- Price
- $80.00
- Value
- $558,160
- Lin Elizabeth YeuSale
1 Sept 2026, Chief Medical Officer
- Shares
- 4,601
- Price
- $73.86
- Value
- $339,830
- Azamian Bobak R.Sale
17 Jun 2026, President/CEO and Board Chair
- Shares
- 10,000
- Price
- $61.55
- Value
- $615,488
- Farrow Jeffrey SSale
16 Jun 2026, See Remarks
- Shares
- 14,396
- Price
- $60.95
- Value
- $877,436
- Goodrich KatherineSale
15 Jun 2026, Board
- Shares
- 2,954
- Price
- $62.08
- Value
- $183,384
- Link William J PhdSale
15 Jun 2026, Board
- Shares
- 12,500
- Price
- $62.12
- Value
- $776,495
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Tarsus Pharmaceuticals
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 43
- Sector median
- 53
Categories against the sector medianMedian of 714 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Tango TherapeuticsTNGX $4.34B45
- Xenon PharmaceuticalsXENE $4.14B37
- Amylyx PharmaceuticalsAMLX $4.09B43
- AbCellera BiologicsABCL $3.9B38
- Enliven TherapeuticsELVN $3.77B45
- Iovance BiotherapeuticsIOVA $3.74B43
- Denali TherapeuticsDNLI $3.72B37
- Viking TherapeuticsVKTX $3.63B34
ETFs that hold Tarsus Pharmaceuticals
Held by 11 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.20% | 0.35% | €1.21B |
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.13% | 0.30% | €185.82M |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.11% | 0.30% | €4.22B |
Show 5 more
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.10% | 0.30% | €2.17B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.03% | 0.43% | €2.48B |
| State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS | 0.02% | 0.45% | €1.53B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.01% | 0.35% | €434.1M |
| UBS MSCI USA Select Factor Mix UCITS ETF USD accUSUE | 0.01% | 0.25% | €175.89M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Oct 2021)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.